Combined antidepressant treatment.

Ketamine: stimulating antidepressant treatment?

SUMMARY The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ke...

A study of refractory cases of depressive illnesses and their response to combined antidepressant treatment.

Suicidal risk during antidepressant treatment.

To the Editor: The recent report by Stübner and colleagues1 of a large clinical survey of over 142,000 European patients treated with various antidepressants from 1993–2008 concluded that antidepressant treatment may, rarely, increase risks of suicidal behavior. The rate of suicide was 3/142,090 in an unspecified exposure time, or 2.1/100,000, and for suicide attempts, 18/142,090, or 12.7/100,0...

Pharmacogenomics of antidepressant treatment effects

There has been considerable promise and hope that pharmacogenomics will optimize existing treatments for major depression, as well as identify novel targets for drug discovery. Immediately after the sequencing of the human genome, there was much hope that tremendous progress in pharmacogenomics would rapidly be achieved. In the past 10 years this initial enthusiasm has been replaced by a more s...

Suicide risk during antidepressant treatment.

OBJECTIVE In March 2004 the U.S. Food and Drug Administration (FDA) warned physicians and patients regarding increased risk of suicide with 10 newer antidepressant drugs. Available data leave considerable uncertainty regarding actual risk of suicide attempt and death by suicide during antidepressant treatment. The authors used population-based data to evaluate the risk of suicide death and seri...